The skinny on obesity and plasma cell myeloma: A review of the literature

Bone Marrow Transplantation

Volumn 49, Issue 8, 2014, Pages 1009-1015

  Carson, K R ^a   Bates, M L ^b   Tomasson, M H ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COMPLICATION; HUMAN; METABOLISM; MULTIPLE MYELOMA; OBESITY; PRECANCEROUS CONDITIONS; RISK FACTOR;

HUMANS; MULTIPLE MYELOMA; OBESITY; PRECANCEROUS CONDITIONS; RISK FACTORS;

EID: 84905709032     PISSN: 02683369     EISSN: 14765365     Source Type: Journal    
DOI: 10.1038/bmt.2014.71     Document Type: Review

References (107)

1. Ogden CL, Carroll MD, Curtin LR, McDowell MA, Tabak CJ, Flegal KM. Prevalence of overweight and obesity in the United States, 1999-2004. JAMA 2006; 295: 1549-1555.
2. Flegal KM, Carroll MD, Ogden CL, Curtin LR, Flegal KM, Carroll MD et al. Prevalence and trends in obesity among US adults, 1999-2008. JAMA 2010; 303: 235-241.
3. Berrington de Gonzalez A, Hartge P, Cerhan JR, Flint AJ, Hannan L, MacInnis RJ et al. Body-mass index and mortality among 1.46 million white adults. N Engl J Med 2010; 363: 2211-2219.
4. Jee SH, Sull JW, Park J, Lee SY, Ohrr H, Guallar E et al. Body-mass index and mortality in Korean men and women. N Engl J Med 2006; 355: 779-787.
5. Kramer CK, Zinman B, Retnakaran R. Are metabolically healthy overweight and obesity benign conditions?: A systematic review and meta-analysis. Ann Intern Med 2013; 159: 758-769.
6. Adams KF, Schatzkin A, Harris TB, Kipnis V, Mouw T, Ballard-Barbash R et al. Overweight, obesity, and mortality in a large prospective cohort of persons 50 to 71 years old. N Engl J Med 2006; 355: 763-778.
7. Calle EE, Rodriguez C, Walker-Thurmond K, Thun MJ, Calle EE, Rodriguez C et al. Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. N Engl J Med 2003; 348: 1625-1638.
8. Wallin A, Larsson SC. Body mass index and risk of multiple myeloma: a metaanalysis of prospective studies. Eur J Cancer 2011; 47: 1606-1615.
9. SEER Stat Fact Sheets: Myeloma. 2013. (Accessed 3 August 2013, at http:// seer.cancer.gov/statfacts/html/mulmy.html.).
10. Landgren O, Kyle RA, Pfeiffer RM, Katzmann JA, Caporaso NE, Hayes RB et al. Monoclonal gammopathy of undetermined significance (MGUS) consistently precedes multiple myeloma: a prospective study. Blood 2009; 113: 5412-5417.
11. Kyle RA, Rajkumar SV, Melton LJ. Prevalence of monoclonal gammopathy of undetermined significance - Reply. N Engl J Med 2006; 354: 2832-2832.
12. Kyle RA, Therneau TM, Rajkumar SV, Offord JR, Larson DR, Plevak MF et al. A long-term study of prognosis in monoclonal gammopathy of undetermined significance. N Engl J Med 2002; 346: 564-569.
13. Rajkumar SV. Multiple myeloma: 2013 update on diagnosis, risk-stratification, and management. Am J Hematol 2013; 88: 225-235.
14. Birmann BM, Giovannucci E, Rosner B, Anderson KC, Colditz GA. Body mass index, physical activity, and risk of multiple myeloma. Cancer Epidemiol Biomarkers Prev 2007; 16: 1474-1478.
15. Korde N, Kristinsson SY, Landgren O. Monoclonal gammopathy of undetermined significance (MGUS) and smoldering multiple myeloma (SMM): novel biological insights and development of early treatment strategies. Blood 2011; 117: 5573-5581.
16. Nassis GP, Papantakou K, Skenderi K, Triandafillopoulou M, Kavouras SA, Yannakoulia M et al. Aerobic exercise training improves insulin sensitivity without changes in body weight, body fat, adiponectin, and inflammatory markers in overweight and obese girls. Metabolism 2005; 54: 1472-1479.
17. Petersen AM, Pedersen BK. The anti-inflammatory effect of exercise. J Appl Physiol 2005; 98: 1154-1162.
18. Han X, Zheng T, Foss F, Holford TR, Ma S, Zhao P et al. Vegetable and fruit intake and non-Hodgkin lymphoma survival in Connecticut women. Leuk Lymphoma 2010; 51: 1047-1054.
19. Courneya KS, Sellar CM, Stevinson C, McNeely ML, Peddle CJ, Friedenreich CM et al. Randomized controlled trial of the effects of aerobic exercise on physical functioning and quality of life in lymphoma patients. J Clin Oncol 2009; 27: 4605-4612.
20. Chlebowski RT, Blackburn GL, Thomson CA, Nixon DW, Shapiro A, Hoy MK et al. Dietary fat reduction and breast cancer outcome: interim efficacy results from the Women's Intervention Nutrition Study. J Natl Cancer Inst 2006; 98: 1767-1776.
21. Holmes MD, Chen WY, Feskanich D, Kroenke CH, Colditz GA, Holmes MD et al. Physical activity and survival after breast cancer diagnosis. JAMA 2005; 293: 2479-2486.
22. Renehan AG, Tyson M, Egger M, Heller RF, Zwahlen M. Body-mass index and incidence of cancer: a systematic review and meta-analysis of prospective observational studies. Lancet 2008; 371: 569-578.
23. Blair CK, Cerhan JR, Folsom AR, Ross JA. Anthropometric characteristics and risk of multiple myeloma. Epidemiology 2005; 16: 691-694.
24. Britton JA, Khan AE, Rohrmann S, Becker N, Linseisen J, Nieters A et al. Anthropometric characteristics and non-Hodgkin's lymphoma and multiple myeloma risk in the European Prospective Investigation into Cancer and Nutrition (EPIC). Haematologica 2008; 93: 1666-1677.
25. Engeland A, Tretli S, Hansen S, Bjorge T. Height and body mass index and risk of lymphohematopoietic malignancies in two million Norwegian men and women. Am J Epidemiol 2007; 165: 44-52.
26. Fernberg P, Odenbro A, Bellocco R, Boffetta P, Pawitan Y, Zendehdel K et al. Tobacco use, body mass index, and the risk of leukemia and multiple myeloma: a nationwide cohort study in Sweden. Cancer Res 2007; 67: 5983-5986.
27. Kanda J, Matsuo K, Inoue M, Iwasaki M, Sawada N, Shimazu T et al. Association of anthropometric characteristics with the risk of malignant lymphoma and plasma cell myeloma in a Japanese population: a population-based cohort study. Cancer Epidemiol Biomarkers Prev 2010; 19: 1623-1631.
28. Khan MM, Mori M, Sakauchi F, Matsuo K, Ozasa K, Tamakoshi A. Risk factors for multiple myeloma: evidence from the Japan Collaborative Cohort (JACC) study. Asian Pac J Cancer Prev 2006; 7: 575-581.
29. Lu Y, Sullivan-Halley J, Henderson KD, Ma H, Horn-Ross PL, Reynolds P et al. Anthropometric characteristics and multiple myeloma risk. Epidemiology 2010; 21: 272-273.
30. Pylypchuk RD, Schouten LJ, Goldbohm RA, Schouten HC, van den Brandt PA. Body mass index, height, and risk of lymphatic malignancies: a prospective cohort study. Am J Epidemiol 2009; 170: 297-307.
31. Reeves GK, Pirie K, Beral V, Green J, Spencer E, Bull D. Cancer incidence and mortality in relation to body mass index in the Million Women Study: cohort study. BMJ 2007; 335: 1134.
32. Samanic C, Chow WH, Gridley G, Jarvholm B, Fraumeni JF Jr. Relation of body mass index to cancer risk in 362,552 Swedish men. Cancer Causes Control 2006; 17: 901-909.
33. Soderberg KC, Kaprio J, Verkasalo PK, Pukkala E, Koskenvuo M, Lundqvist E et al. Overweight, obesity and risk of haematological malignancies: a cohort study of Swedish and Finnish twins. Eur J Cancer 2009; 45: 1232-1238.
34. Troy JD, Hartge P, Weissfeld JL, Oken MM, Colditz GA, Mechanic LE et al. Associations between anthropometry, cigarette smoking, alcohol consumption, and non-Hodgkin lymphoma in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial. Am J Epidemiol 2010; 171: 1270-1281.
35. Levi Z, Kark JD, Barchana M, Liphshitz I, Zavdi O, Tzur D et al. Measured body mass index in adolescence and the incidence of colorectal cancer in a cohort of 1.1 million males. Cancer Epidemiol Biomarkers Prev 2011; 20: 2524-2531.
36. Birmann BM, Suppan CA, Colditz GA. Body shape throughout life, long-term weight cycling, and risk of multiple myeloma in the Nurses' Health Study. Cancer Prev Res 2011; 4(Suppl 1): A79.
37. Must A, Strauss RS. Risks and consequences of childhood and adolescent obesity. Int J Obesity 1999; 23: S2-S11.
38. Rowland ML. Self-reported weight and height. Am J Clin Nutr 1990; 52: 1125-1133.
39. Despres JP. Body fat distribution and risk of cardiovascular disease an update. Circulation 2012; 126: 1301-1313.
40. Dennis KE, Goldberg AP. Differential-effects of body fatness and body-fat distribution on risk-factors for cardiovascular-disease in women - impact of weight-loss. Arterioscler Thromb 1993; 13: 1487-1494.
41. Thompson MA, Kyle RA, Melton LJ3rd, Plevak MF, Rajkumar SV. Effect of statins, smoking and obesity on progression of monoclonal gammopathy of undetermined significance: a case-control study. Haematologica 2004; 89: 626-628.
42. Brown LM, Gridley G, Pottern LM, Baris D, Swanso CA, Silverman DT et al. Diet and nutrition as risk factors for multiple myeloma among blacks and whites in the United States. Cancer Causes Control 2001; 12: 117-125.
43. Hosgood HD 3rd, Baris D, Zahm SH, Zheng T, Cross AJ. Diet and risk of multiple myeloma in Connecticut women. Cancer Causes Control 2007; 18: 1065-1076.
44. Fritschi L, Ambrosini GL, Kliewer EV, Johnson KC, Canadian Cancer Registries Epidemiologic Research G. Dietary fish intake and risk of leukaemia, multiple myeloma, and non-Hodgkin lymphoma. Cancer Epidemiol Biomarkers Prev 2004; 13: 532-537.
45. He K, Hu FB, Colditz GA, Manson JE, Willett WC, Liu S. Changes in intake of fruits and vegetables in relation to risk of obesity and weight gain among middleaged women. Int J Obes Relat Metab Disord 2004; 28: 1569-1574.
46. Thune I, Brenn T, Lund E, Gaard M. Physical activity and the risk of breast cancer. N Engl J Med 1997; 336: 1269-1275.
47. Walter RB, Buckley SA, White E. Regular recreational physical activity and risk of hematologic malignancies: results from the prospective VITamins And lifestyle (VITAL) study. Ann Oncol 2013; 24: 1370-1377.
48. Vermaete NV, Wolter P, Verhoef GE, Kollen BJ, Kwakkel G, Schepers L et al. Physical activity and risk of lymphoma: a meta-analysis. Cancer Epidemiol Biomarkers Prev 2013; 22: 1173-1184.
49. McDermott AY, Mernitz H. Exercise and older patients: prescribing guidelines. Am Fam Physician 2006; 74: 437-444.
50. Kraemer WJ, Marchitelli L, Gordon SE, Harman E, Dziados JE, Mello R et al. Hormonal and growth factor responses to heavy resistance exercise protocols. J Appl Physiol (1985) 1990; 69: 1442-1450.
51. Bruun JM, Helge JW, Richelsen B, Stallknecht B. Diet and exercise reduce low-grade inflammation and macrophage infiltration in adipose tissue but not in skeletal muscle in severely obese subjects. Am J Physiol Endocrinol Metab 2006; 290: E961-E967.
52. Woods JA, Vieira VJ, Keylock KT. Exercise, inflammation, and innate immunity. Immunol Allergy Clin North Am 2009; 29: 381-393.
53. Church TS, Martin CK, Thompson AM, Earnest CP, Mikus CR, Blair SN. Changes in weight, waist circumference and compensatory responses with different doses of exercise among sedentary, overweight postmenopausal women. PloS One 2009; 4: e4515.
54. Donnelly JE, Smith BK. Is exercise effective for weight loss with ad libitum diet? energy balance, compensation, and gender differences. Exerc Sport Sci Rev 2005; 33: 169-174.
55. Chandran M, Phillips SA, Ciaraldi T, Henry RR. Adiponectin: more than just another fat cell hormone? Diabetes care 2003; 26: 2442-2450.
56. Hug C, Lodish HF. The role of the adipocyte hormone adiponectin in cardiovascular disease. Curr Opin Pharmacol 2005; 5: 129-134.
57. Hofmann JN, Liao LM, Pollak MN, Wang Y, Pfeiffer RM, Baris D et al. A prospective study of circulating adipokine levels and risk of multiple myeloma. Blood 2012; 120: 4418-4420.
58. Dalamaga M, Karmaniolas K, Panagiotou A, Hsi A, Chamberland J, Dimas C et al. Low circulating adiponectin and resistin, but not leptin, levels are associated with multiple myeloma risk: a case-control study. Cancer Causes Control 2009; 20: 193-199.
59. Fowler JA, Lwin ST, Drake MT, Edwards JR, Kyle RA, Mundy GR et al. Host-derived adiponectin is tumor-suppressive and a novel therapeutic target for multiple myeloma and the associated bone disease. Blood 2011; 118: 5872-5882.
60. Dalamaga M, Diakopoulos KN, Mantzoros CS. The role of adiponectin in cancer: a review of current evidence. Endocr Rev 2012; 33: 547-594.
61. Oh DK, Ciaraldi T, Henry RR. Adiponectin in health and disease. Diabetes Obes Metab 2007; 9: 282-289.
62. Renehan AG, Roberts DL, Dive C. Obesity and cancer: pathophysiological and biological mechanisms. Arch Physiol Biochem 2008; 114: 71-83.
63. Kelesidis T, Kelesidis I, Chou S, Mantzoros CS. Narrative review: the role of leptin in human physiology: emerging clinical applications. Ann Intern Med 2010; 152: 93-100.
64. Considine RV, Sinha MK, Heiman ML, Kriauciunas A, Stephens TW, Nyce MR et al. Serum immunoreactive-leptin concentrations in normal-weight and obese humans. N Engl J Med 1996; 334: 292-295.
65. Guo S, Liu M, Wang G, Torroella-Kouri M, Gonzalez-Perez RR. Oncogenic role and therapeutic target of leptin signaling in breast cancer and cancer stem cells. Biochim Biophys Acta 2012; 1825: 207-222.
66. Saglam K, Aydur E, Yilmaz M, Goktas S. Leptin influences cellular differentiation and progression in prostate cancer. J Urol 2003; 169: 1308-1311.
67. Pamuk GE, Demir M, Harmandar F, Yesil Y, Turgut B, Vural O. Leptin and resistin levels in serum of patients with hematologic malignancies: correlation with clinical characteristics. Exp Oncol 2006; 28: 241-244.
68. Reseland JE, Reppe S, Olstad OK, Hjorth-Hansen H, Brenne AT, Syversen U et al. Abnormal adipokine levels and leptin-induced changes in gene expression profiles in multiple myeloma. Eur J Haematol 2009; 83: 460-470.
69. LeRoith D, Roberts CT Jr. The insulin-like growth factor system and cancer. Cancer Lett 2003; 195: 127-137.
70. Kahn BB, Flier JS. Obesity and insulin resistance. J Clin Invest 2000; 106: 473-481.
71. Conover CA, Lee PD, Kanaley JA, Clarkson JT, Jensen MD. Insulin regulation of insulin-like growth factor binding protein-1 in obese and nonobese humans. J Clin Endocrinol Metab 1992; 74: 1355-1360.
72. Ferlin M, Noraz N, Hertogh C, Brochier J, Taylor N, Klein B. Insulin-like growth factor induces the survival and proliferation of myeloma cells through an interleukin-6-independent transduction pathway. Br J Haematol 2000; 111: 626-634.
73. Georgii-Hemming P, Wiklund HJ, Ljunggren O, Nilsson K. Insulin-like growth factor I is a growth and survival factor in human multiple myeloma cell lines. Blood 1996; 88: 2250-2258.
74. Sprynski AC, Hose D, Kassambara A, Vincent L, Jourdan M, Rossi JF et al. Insulin is a potent myeloma cell growth factor through insulin/IGF-1 hybrid receptor activation. Leukemia 2010; 24: 1940-1950.
75. Mitsiades CS, Mitsiades NS, McMullan CJ, Poulaki V, Shringarpure R, Akiyama M et al. Inhibition of the insulin-like growth factor receptor-1 tyrosine kinase activity as a therapeutic strategy for multiple myeloma, other hematologic malignancies, and solid tumors. Cancer Cell 2004; 5: 221-230.
76. Jernberg-Wiklund H, Nilsson K. Control of apoptosis in human multiple myeloma by insulin-like growth factor I (IGF-I). Adv Cancer Res 2007; 97: 139-165.
77. Yee D. Insulin-like growth factor receptor inhibitors: baby or the bathwater? J Natl Cancer Inst 2012; 104: 975-981.
78. Standal T, Borset M, Lenhoff S, Wisloff F, Stordal B, Sundan A et al. Serum insulinlike growth factor is not elevated in patients with multiple myeloma but is still a prognostic factor. Blood 2002; 100: 3925-3929.
79. Castillo JJ, Mull N, Reagan JL, Nemr S, Mitri J. Increased incidence of non-Hodgkin lymphoma, leukemia, and myeloma in patients with diabetes mellitus type 2: a meta-analysis of observational studies. Blood 2012; 119: 4845-4850.
80. Birmann BM, Neuhouser ML, Rosner B, Albanes D, Buring JE, Giles GG et al. Prediagnosis biomarkers of insulin-like growth factor-1, insulin, and interleukin-6 dysregulation and multiple myeloma risk in the Multiple Myeloma Cohort Consortium. Blood 2012; 120: 4929-4937.
81. Eder K, Baffy N, Falus A, Fulop A. The major inflammatory mediator interleukin-6 and obesity. Inflamm Res 2009; 58: 727-736.
82. Zhang XG, Klein B, Bataille R. Interleukin-6 is a potent myeloma-cell growth factor in patients with aggressive multiple myeloma. Blood 1989; 74: 11-13.
83. Hardin J, MacLeod S, Grigorieva I, Chang R, Barlogie B, Xiao H et al. Interleukin-6 prevents dexamethasone-induced myeloma cell death. Blood 1994; 84: 3063-3070.
84. Bataille R, Barlogie B, Lu ZY, Rossi JF, Lavabre-Bertrand T, Beck T et al. Biologic effects of anti-interleukin-6 murine monoclonal antibody in advanced multiple myeloma. Blood 1995; 86: 685-691.
85. Kurzrock R, Voorhees PM, Casper C, Furman RR, Fayad L, Lonial S et al. A Phase I, open-label study of siltuximab, an anti-il-6 monoclonal antibody, in patients with B-cell non-Hodgkin lymphoma, multiple myeloma, or Castleman disease. Clin Cancer Res 2013; 19: 3659-3670.
86. Dickson TMC, Kusnierz-Glaz CR, Blume KG, Negrin RS, Hu WW, Shizuru JA et al. Impact of admission body weight and chemotherapy dose adjustment on the outcome of autologous bone marrow transplantation. Biol Blood Marrow Transplant 1999; 5: 299-305.
87. DuBois D, DuBois EF. A formula to estimate the approximate surface area if height and weight be known. Arch Intern Med 1916; 17: 863-871.
88. Vogl DT, Wang T, Perez WS, Stadtmauer EA, Heitjan DF, Lazarus HM et al. Effect of Obesity on Outcomes after Autologous Hematopoietic Stem Cell Transplantation for Multiple Myeloma. Biol Blood Marrow Transplant 2011; 17: 1765-1774.
89. Griggs JJ, Mangu PB, Anderson H, Balaban EP, Dignam JJ, Hryniuk WM et al. Appropriate chemotherapy dosing for obese adult patients with cancer: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol 2012; 30: 1553-1561.
90. Bruno B, Rotta M, Patriarca F, Mordini N, Allione B, Carnevale-Schianca F et al. A comparison of allografting with autografting for newly diagnosed myeloma. New Engl J Med 2007; 356: 1110-1120.
91. Garban F, Attal M, Michallet M, Hulin C, Bourhis JH, Yakoub-Agha I et al. Prospective comparison of autologous stem cell transplantation followed by dose-reduced allograft (IFM99-03 trial) with tandem autologous stem cell transplantation (IFM99-04 trial) in high-risk de novo multiple myeloma. Blood 2006; 107: 3474-3480.
92. Guh DP, Zhang W, Bansback N, Amarsi Z, Birmingham CL, Anis AH. The incidence of co-morbidities related to obesity and overweight: a systematic review and meta-analysis. BMC Public Health 2009; 9: 88.
93. Sorror ML, Maris MB, Storb R, Baron F, Sandmaier BM, Maloney DG et al. Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT. Blood 2005; 106: 2912-2919.
94. Ballen KK, Gluckman E, Broxmeyer HE. Umbilical cord blood transplantation: the first 25 years and beyond. Blood 2013; 122: 491-498.
95. Fleming DR, Rayens MK, Garrison J. Impact of obesity on allogeneic stem cell transplant patients: a matched case-controlled study. Am J Med 1997; 102: 265-268.
96. Nikolousis E, Nagra S, Paneesha S, Delgado J, Holder K, Bratby L et al. Allogeneic transplant outcomes are not affected by body mass index (BMI) in patients with haematological malignancies. Ann Hematol 2010; 89: 1141-1145.
97. Fuji S, Kim S-W, Yoshimura K-i, Akiyama H, Okamoto S-i, Sao H et al. Possible association between obesity and posttransplantation complications including infectious diseases and acute graft-versus-host disease. Biol Blood Marrow Transplant 2009; 15: 73-82.
98. Beason TS, Chang SH, Sanfilippo KM, Luo S, Colditz GA, Vij R et al. Influence of body mass index on survival in veterans with multiple myeloma. Oncologist 2013; 18: 1074-1079.
99. Nestle M, Jacobson MF. Halting the obesity epidemic: a public health policy approach. Public health reports 2000; 115: 12-24.
100. Jarlenski MP, Gudzune KA, Bennett WL, Cooper LA, Bleich SN. Insurance coverage for weight loss: overweight adults' views. Am J Prev Med 2013; 44: 453-458.
101. Appel LJ, Clark JM, Yeh H-C, Wang N-Y, Coughlin JW, Daumit G et al. Comparative Effectiveness of Weight-Loss Interventions in Clinical Practice. N Engl J Med 2011; 365: 1959-1968.
102. Chang SH, Stoll CR, Colditz GA. Cost-effectiveness of bariatric surgery: should it be universally available? Maturitas 2011; 69: 230-238.
103. Mateos M-V, Hernández M-T, Giraldo P, de la Rubia J, de Arriba F, Corral LL et al. Lenalidomide plus dexamethasone for high-risk smoldering multiple myeloma. New Engl J Med 2013; 369: 438-447.
104. Birmann BM, Giovannucci E, Rosner B, Colditz GA. Regular aspirin use and risk of multiple myeloma: a prospective analysis in the Health Professionals Follow-up Study and Nurses' Health Study. Cancer Prev Res 2013; 7: 33-41.
105. Hakimi AA, Chen L, Kim PH, Sjoberg D, Glickman L, Walker MR et al. The impact of metformin use on recurrence and cancer-specific survival in clinically localized high-risk renal cell carcinoma. Can Urol Assoc J 2013; 7: E687-E691.
106. Ko EM, Walter P, Jackson A, Clark L, Franasiak J, Bolac C et al. Metformin is associated with improved survival in endometrial cancer. Gynecol Oncol 2013; 132: 438-442.
107. Peeters PJ, Bazelier MT, Vestergaard P, Leufkens HG, Schmidt MK, de Vries F et al. Use of metformin and survival of diabetic women with breast cancer. Curr Drug Saf 2013; 8: 357-363